The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Collagen Solutions Acquired by Rosen’s Diversified

20 Oct 2020 07:03

RNS Number : 5425C
Collagen Solutions PLC
20 October 2020
 

 

 

20 October 2020

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Collagen Solutions Plc Acquired by Rosen's Diversified, Inc.

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that today Rosen's Diversified, Inc. ("RDI") declared that its offer to acquire Collagen Solutions plc (the "Offer") had become wholly unconditional and as a result, Collagen Solutions will become part of the RDI Group.

 

RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Minnesota near the Company's U.S. offices. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.

 

Jamal Rushdy, CEO of Collagen Solutions said: "We have made tremendous progress in our vision to be the industry's first choice for regenerative biomaterials. We believe that being part of RDI will generate significant growth opportunities and create enhanced value for the benefit of all stakeholders and in particular our employees, customers and suppliers. I am optimistic and excited for the potential for continued momentum and greater opportunity for Collagen Solutions." 

 

Wade Rosen, Director of RDI and Executive Vice President of Corporate Development of SLS said: "Collagen Solutions represents an attractive strategic and cultural fit with SLS and we have been highly impressed by the long-term vision and ethos of the Company. The successful completion of the Offer will now provide a foundation for SLS to become a major tissue provider in North America, leveraging the RDI Group's local porcine and bovine harvest, logistics and distribution capabilities in the United States. Collagen's international presence will also provide a platform for SLS to extend its supply of porcine and bovine tissue into the EMEA and APAC regions."

 

England & Company, LLC and Goodbody Stockbrokers UC acted, in relation to the Offer, as joint financial advisers to Collagen Solutions. Shepherd and Wedderburn LLP acted as legal adviser to Collagen Solutions.

 

Strand Hanson and Faegre Drinker acted, in relation to the Offer, as sole financial adviser and legal adviser to RDI, respectively.

 

Enquiries:

Collagen Solutions PlcJamal Rushdy, CEOHilary Spence, CFO

via Walbrook

England & Company LLC(Joint Financial Adviser to Collagen Solutions Plc)Craig EnglandPaul Teitelbaum

Tel: +1 (212) 235-0850

Goodbody Stockbrokers UC(Rule 3 Adviser and Joint Financial Adviser to Collagen Solutions Plc)Stephen KaneChristopher McAuliffe

Tel: +353 (0) 1 667 0400

Cenkos Securities plc(Nominated Adviser and Broker to Collagen Solutions Plc)Giles BallenyMax Gould

Tel: +44 (0) 207 397 8900

Walbrook PR Ltd(Financial PR adviser to Collagen Solutions Plc)Anna Dunphy

Tel: +44 (0) 207 933 8780or collagen@walbrookpr.com

Mob: +44 (0) 7876 741 001

Rosen's Diversified, Inc.David Krawitz, Director of Strategy, Operations and Sales

Tel: +1 (612) 406-5181

Strand Hanson Limited(Financial Adviser to Rosen's Diversified, Inc.)Stuart FaulknerMatthew ChandlerJames DanceJack Botros

Tel: +44 (0) 207 409 3494

Important Notice

England & Company LLC, through its wholly owned subsidiary, England Securities, LLC, is acting as joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of England & Company LLC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither England & Company LLC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of England & Company LLC in connection with this announcement, any statement contained herein or otherwise.

Goodbody Stockbrokers UC, trading as Goodbody, which is regulated in Ireland by the Central Bank of Ireland and in the UK by the Financial Conduct Authority, is acting as sole Rule 3 adviser and joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Goodbody Stockbrokers UC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Goodbody Stockbrokers UC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goodbody Stockbrokers UC in connection with this announcement, any statement contained herein or otherwise.

Cenkos Securities plc, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Cenkos Securities plc nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Cenkos Securities plc nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cenkos Securities plc in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQDGBDGLXBDGGC
Date   Source Headline
10th Mar 20152:56 pmRNSDirector/PDMR Shareholding
10th Mar 20157:03 amRNSRegulatory Approvals for Collagen Solutions Client
10th Mar 20157:03 amRNSTrading Statement and Acquisition Update
9th Jan 20157:00 amRNSInvestor Presentation
7th Jan 20154:04 pmRNSHolding(s) in Company
7th Jan 20157:00 amRNSCEO Presents at OneMedForum
5th Jan 20157:00 amRNSContract signed with Globus Medical Inc.
22nd Dec 20147:00 amRNSNew contract to supply Desu Medical
17th Dec 201410:54 amRNSHolding(s) in Company
15th Dec 20147:00 amRNSContract signed with Kyeron
12th Dec 201410:50 amRNSHolding(s) in Company
10th Dec 20147:00 amRNSSouthern Lights Biomaterials Acquisition Completed
24th Nov 201411:48 amRNSGrant of Options
21st Nov 20147:30 amRNSSchedule 1 - Collagen Solutions Plc
21st Nov 20147:00 amRNSAcquisition
21st Nov 20147:00 amRNSChange of Adviser
21st Nov 20147:00 amRNSHalf Yearly Report
22nd Oct 201412:30 pmRNSHolding(s) in Company
17th Oct 20147:00 amRNSJellagen Collaboration
10th Sep 201412:23 pmRNSHolding(s) in Company
3rd Sep 20147:00 amRNSAppointment to Scientific Advisory Board
27th Aug 201411:52 amRNSResult of AGM
29th Jul 20143:19 pmRNSHolding(s) in Company
18th Jul 20147:00 amRNSPosting of Annual Report & Notice of AGM
10th Jul 20147:00 amRNSFinal Results
3rd Jul 20147:00 amRNSChange of Registered Office
10th Jun 20147:00 amRNSExclusive Licencing of Intellectual Property
19th May 20147:00 amRNSProfessor Robert Brown joins as Scientific Adviser
15th May 20147:00 amRNSExcellagen® enters new clinical trial
26th Mar 201410:48 amRNSHolding(s) in Company
3rd Mar 20147:00 amRNSAppointment of Director
27th Dec 201312:25 pmRNSDirector Shareholding
27th Dec 201311:58 amRNSResult of GM
17th Dec 201310:00 amRNSAnnouncement by Cardium Therapeutics
16th Dec 20139:03 amRNSSchedule 1 - Healthcare Investment Opportunities
10th Dec 20137:00 amRNSHalf Yearly Report
10th Dec 20137:00 amRNSProposed acquisition
19th Aug 201311:06 amRNSHolding(s) in Company
1st Aug 20131:43 pmRNSHolding(s) in Company
2nd May 201312:00 pmRNSHolding(s) in Company
22nd Apr 201312:19 pmRNSHolding(s) in Company
9th Apr 201310:57 amRNSHolding in Company
8th Apr 20135:41 pmRNSHolding(s) in Company
5th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.